Results 21 to 30 of about 2,201,777 (199)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer [PDF]

Therapeutic Advances in Medical Oncology, 2022
The discovery of activating mutations in epidermal growth factor receptor (EGFR) in non-small-cell lung cancer transformed the care and prognosis of patients and heralded the era of ‘personalized medicine’ in thoracic oncology.
Sun Min Lim, Byoung Chul Cho, Jiyun Lee, Ross Soo, Zofia Piotrowska   +4 more
core   +6 more sources

SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma

Molecular Oncology
Son of sevenless 1 and 2 (SOS1 and SOS2) are RAS guanine nucleotide exchange factors (RasGEFs) that mediate physiologic and pathologic receptor tyrosine kinase (RTK)‐dependent RAS activation.
Patricia L. Theard, Amanda J. Linke, Nancy E. Sealover, Brianna R. Daley, Johnny Yang, Katherine Cox, Robert L. Kortum   +6 more
doaj   +2 more sources

A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib [PDF]

Cell Reports Medicine
: Activating EGFR (epidermal growth factor receptor) mutations can be inhibited by specific tyrosine kinase inhibitors (TKIs), which have changed the landscape of lung cancer therapy. However, due to secondary mutations and bypass receptors, such as AXL (
Simoni-Nieves, Arturo, Marrocco, Ilaria, Chatterjee, Rishita, Van Daele, Marieke, Haga, Yuya, Selvadurai, Boobash-Raj, Salame, Tomer-Meir, Lauriola, Mattia, Yarden, Yosef, Giri, Suvendu, Gupta, Nitin, Zerbib, Mirie, Love, Danielle, Romaniello, Donatella, Lindzen, Moshit, Tsutsumi, Yasuo, Oren, Roni   +16 more
core   +7 more sources

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells [PDF]

Nature Communications, 2019
Resistance to the new generation EGFR-TKI, Osimertinib, can emerge in patients with EGFR-mutated lung cancer. Here, the authors show that AXL, which is activated by osimertinib, can promote the emergence of tolerant lung cancer cell thus conferring ...
Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Keiko Tanimura, Yuta Adachi, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Luiz H. Araujo, Mariana Boroni, Akihiro Yoshimura, Shinsuke Shiotsu, Isao Matsumoto, Satoshi Watanabe, Toshiaki Kikuchi, Satoru Miura, Hiroshi Tanaka, Takeshi Kitazaki, Hiroyuki Yamaguchi, Hiroshi Mukae, Junji Uchino, Hisanori Uehara, Koichi Takayama, Seiji Yano   +23 more
doaj   +2 more sources

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation

BMC Cancer, 2018
Background Among non-small cell lung cancer (NSCLC) patients with acquired T790 M mutation resistance to first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), 71% are likely to benefit from osimertinib.
Lin-Peng Zheng, Li-Ying Chen, Xing-Yun Liao, Zi-Han Xu, Zheng-Tang Chen, Jian-Guo Sun   +5 more
doaj   +2 more sources

Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC

Cell Reports
Summary: Leptomeningeal metastases (LMs) remain a devastating complication of non-small cell lung cancer (NSCLC), particularly following osimertinib resistance.
Kai Yin, Si-Yang Maggie Liu, Mei-Mei Zheng, Yi-Long Wu, Liang Li, Yangqiu Li, Bin-Chao Wang, Jia-Xin Lin, Wei-Bang Guo, Zhen Wang, Ben-Yuan Jiang, Wen-Pu Lai, Xu-Chao Zhang, E.-E. Ke, Zhi-Hong Chen, Shou-Heng Lin, Hua-Jun Chen, Qing Zhou, Xiao-Yan Bai, Yue-Li Sun, Hai-Yan Tu, Fa-Man Xiao, Oscar Junhong Luo, Hao Sun, Lu Zeng, Xue-Ning Yang, Jin-Ji Yang, Yi Pan, Wen-Zhao Zhong, Yang-Si Li   +29 more
core   +4 more sources

Finding chinks in the osimertinib resistance armor [PDF]

Translational Lung Cancer Research, 2020
The use of small molecule inhibitors directed at specific oncogene targets, including epidermal growth factor receptor (EGFR) mutations, has improved outcomes and defined precision medicine for non-small cell lung cancers (NSCLC). However, despite the impressive responses and improvements in survival seen with these agents, they are rarely curative ...
Leal, Jose Luis, Solomon, Benjamin, John, Thomas   +2 more
openaire   +2 more sources

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms

The Clinical Respiratory Journal
Background Osimertinib is approved as a standard treatment for non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation by FDA.
Xin Liao, Tingting He, Xiong Wan, Pian Liu, Jing Li, Yong He, Yubo Wang   +6 more
doaj   +2 more sources

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance [PDF]

Frontiers in Pharmacology, 2022
At present, treatment options for osimertinib resistance are very limited. Dual inhibition of the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) significantly improved the progression-free survival (PFS) of advanced EGFR-mutant non–small cell lung cancer (NSCLC).
Qingli Cui, Yanhui Hu, Qingan Cui, Daoyuan Wu, Yuefeng Mao, Dongyang Ma, Huaimin Liu   +6 more
openaire   +3 more sources

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation

Thoracic Cancer, 2020
Background Osimertinib (AZD9291) is a third‐generation EGFR‐tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR‐mutant non‐small cell lung cancer (NSCLC).
Daisuke Hayakawa, Fumiyuki Takahashi, Yoichiro Mitsuishi, Ken Tajima, Moulid Hidayat, Wira Winardi, Hiroaki Ihara, Koichiro Kanamori, Naohisa Matsumoto, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Kazuya Takamochi, Takuo Hayashi, Yoshiyuki Suehara, Ikuko Takeda Nakamura, Toshihide Ueno, Shinji Kohsaka, Hiroyuki Mano, Kazuhisa Takahashi   +19 more
doaj   +1 more source